Abstract

Semaglutide 2.4 mg is an injectable glucagon-like peptide-1 receptor agonist used for chronic weight management. There is limited published evidence on characteristics of patients treated with semaglutide 2.4 mg in a real-world setting. Our objective was to characterize US patients with obesity initiating semaglutide 2.4 mg compared with patients treated with other branded antiobesity medications (bAOMs) or without bAOM treatment using linked claims and electronic medical record databases.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call